Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy
Interventions: MTP-131 (Bendavia™); Drug
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Cenerimod, Matching Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05161704 or placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: AZD7268, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Darifenacin, Tolterodine, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 162 participants
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tempe, Arizona • San Diego, California + 9 more

Conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN)
Interventions: AH-008 for Injection, 150 mg, AH-008 for Injection, Placebo; Drug
Lead sponsor: AnHorn Medicines Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypercholesterolemia
Interventions: AZD8233; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Subjects
Interventions: KB15A Vaginal Film, Placebo Vaginal Film; Drug
Lead sponsor: ZabBio Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Healthy Volunteer
Interventions: Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Hypoxia, Desaturation of Blood
Interventions: Non-Invasive Controlled Hypoxia, Introduction of Motion conditions: tapping or rubbing; Device · Other
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Diabetes, Diabetes Mellitus, Type 2, Healthy
Interventions: liraglutide-depot, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions: Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Alzheimer's Disease
Interventions: CHF 5074, placebo; Drug
Lead sponsor: CERESPIR; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Eatontown, NJ 07724, New Jersey

Conditions: Safety Issues
Interventions: VIB9600, Placebos; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK1265744 30 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Lakewood, Colorado • Minneapolis, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: DS-7309, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers, Enteric Hyperoxaluria
Interventions: NOV-001, NB1000S, NB2000P, Placebo; Combination Product · Biological · Drug
Lead sponsor: Novome Biotechnologies Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Daytona Beach, Florida + 15 more

Conditions: Healthy
Interventions: MOA-728; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy
Interventions: PF-06412562; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Crohn's Disease
Interventions: AMG 139; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Berlin, New Jersey • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Healthy
Interventions: IA-14069, Placebo; Drug
Lead sponsor: ILAb Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Phase 1 Study of Intravaginal KB15A

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

SpO2 Accuracy Validation of the OxySoft Sensor Via Reference CO-Oximetry Motion Study

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Safety, Pharmacokinetics and Pharmacodynamics Study of Treatment With CHF 5074 in Healthy Young Male Subjects

A Phase1 Study of VIB9600

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus

Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects

Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

SAD Study of IA-14069